APP and Alzheimer disease: Acute application of levetiracetam (LEV or Keppra®), an antiepileptic drug, can effectively suppress abnormal EEG spike activity, and chronic treatment with LEV can even reverse AD-like phenotypes including synaptic dysfunction, hippocampal remodeling, and learning and memory deficits in human APP transgenic mice[115].